CCL6 Produced by Eosinophils Drives Allergic Airway Inflammation in Mice

Xufei Du,Fei Li,Zhehua Shao,Chao Zhang,Wen Li,Zhihua Chen,Songmin Ying,Huahao Shen
DOI: https://doi.org/10.1183/13993003.congress-2019.pa4363
IF: 24.3
2019-01-01
European Respiratory Journal
Abstract:Background: Chemokine (C-C motif) ligand 6 (CCL6) has recently been identified as a candidate cytokine for asthma; however, the mechanisms by which it contributes to asthma pathogenesis are not well understood. Aims and Objectives: To determine the role of CCL6 in airway inflammation in a murine model of allergic asthma. Methods: The expression of CCL6 were examined in ovalbumin (OVA) -challenged airway inflammation in vivo and in different types of cells under cytokines stimulation in vitro. CCL6 KO mice were used to investigated the effect of CCL6 in allergic asthma. Results: Overexpression of CCL6 was found to be responsible for eosinophilia in bronchoalveolar lavage fluid (BALF), serum and lung tissue after allergic challenge. We confirmed that Eos were higher production of CCL6 than the other types of cells in OVA-challenged asthma model. CCL6 deficiency significantly decreased OVA-induced eosinophil recruitment, goblet cell hyperplasia, Th2 cells increase and Th2 cytokines production in the airways. In addition, based on our previous study, Eos-induced disruption of hematopoietic stem cell (HSC) homeostasis following OVA challenge, which was rescued in the mice lacking CCL6. Conclusions: Eos is the major source of CCL6 production in allergic asthma mouse model. CCL6 deficiency protects against Th2 mediated airway inflammation and Eos-induced HSC impairment. CCL6 might be a promising therapeutic target for eosinophilic asthma.
What problem does this paper attempt to address?